Influenza, Human: all 2,265 studies

Page 5 of 23. Open to participants first (174), then studies with results posted, then the rest; newest registration first within each.

• Prevalence, Strain Circulation and Disease Burden Study of Seasonal Influenza A and B in Panama, Selected Countries of Central America and the Caribbean From the Year 2010 to 2015CompletedNCT02885246Results posted
• The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual VaccinationCompletedNCT02876159Phase 4Results posted
• Open-Label Influenza Vaccine EvaluationCompletedNCT02872311Not applicableResults posted
• A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in RussiaCompletedNCT02858440Phase 3Results posted
• Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-deliveryCompletedNCT02853929Phase 4Results posted
• A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of AgeCompletedNCT02839330Phase 3Results posted
• INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart FailureCompletedNCT02787044Phase 4Results posted
• Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant WomenCompletedNCT02783170Phase 4Results posted
• Cell Mediated Immunity Against RSV and Influenza in a Human Experimental ChallengeCompletedNCT02755948Not applicableResults posted
• Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 SeasonCompletedNCT02743117Phase 4Results posted
• A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of AgeCompletedNCT02719743Phase 2Results posted
• A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate VaccineCompletedNCT02692859Phase 3Results posted
• Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 AdjuvantCompletedNCT02680002Phase 2Results posted
• Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'CompletedNCT02677493Phase 3Results posted
• Evaluation of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal Influenza Vaccine, Fluarix Tetra When Administered According to the Approved Prescribing Information (PI) in Korea.CompletedNCT02663102Results posted
• Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in ChildrenCompletedNCT02649192Phase 2Results posted
• Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated InfluenzaCompletedNCT02635724Phase 3Results posted
• A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy AdultsCompletedNCT02623322Phase 2Results posted
• A Safety and Immunogenicity Study of IVACFLU-A/H5N1CompletedNCT02612909Phase 2/3Results posted
• ED Influenza Therapeutic Pilot Study: Oseltamivir vs. PeramivirCompletedNCT02609399Phase 4Results posted
• A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated InfluenzaCompletedNCT02603952Phase 1/2Results posted
• Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)CompletedNCT02598089Phase 1Results posted
• The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal VaccineCompletedNCT02592486Phase 4Results posted
• Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of AgeCompletedNCT02587221Phase 3Results posted
• A Study of a Seasonal Trivalent Split, Inactivated Influenza VaccineCompletedNCT02585700Phase 1Results posted
• Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)CompletedNCT02583256Phase 3Results posted
• Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza ACompletedNCT02572817Phase 3Results posted
• Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy PatientsCompletedNCT02566265Phase 2Results posted
• Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in AdultsCompletedNCT02563093Phase 4Results posted
• Influenza Immunity in ChildrenCompletedNCT02559505Not applicableResults posted
• Phase 2 Study of TAK-850 in Comparison With Influenza Hemagglutinin (HA) Vaccine in Healthy Adult ParticipantsCompletedNCT02555618Phase 2Results posted
• Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 YearsCompletedNCT02550197Phase 3Results posted
• Efficacy & Safety of Nasal Influenza Immunisation in ChildrenCompletedNCT02549365Phase 4Results posted
• A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of AgeCompletedNCT02545543Phase 3Results posted
• Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy ChildrenCompletedNCT02539108Phase 4Results posted
• A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A InfectionCompletedNCT02532283Phase 2Results posted
• Characterisation of a New Wild-Type H3N2 Virus for the Human Viral Challenge ModelCompletedNCT02525055Not applicableResults posted
• Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza VaccinationTerminatedNCT02485639Phase 4Results posted
• Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean AdultsCompletedNCT02480998Phase 1/2Results posted
• Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 SeasonCompletedNCT02473510Phase 4Results posted
• Safety, Tolerability and Clinical Effect of Danirixin in Adults With InfluenzaCompletedNCT02469298Phase 2Results posted
• Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly SubjectsCompletedNCT02467842Phase 3Results posted
• Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and OlderCompletedNCT02464163Phase 1/2Results posted
• Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in IndiaCompletedNCT02451358Phase 3Results posted
• Inactivated Influenza Vaccine Delivered by Microneedle Patch or by Hypodermic NeedleCompletedNCT02438423Phase 1Results posted
• A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to Healthy Adult Subjects.CompletedNCT02427750Phase 2Results posted
• Safety and Protective Efficacy of FF-3 Dry Powder in Healthy Subjects Infected With Influenza Challenge StrainCompletedNCT02423577Phase 2Results posted
• Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-deliveryCompletedNCT02422264Phase 4Results posted
• A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza VaccinesCompletedNCT02415842Results posted
• Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and AdolescentsCompletedNCT02387294Phase 3Results posted
• Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy VolunteersTerminatedNCT02385123Phase 4Results posted
• Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 SeasonCompletedNCT02381418Phase 3Results posted
• Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Volunteer Human Challenge ModelCompletedNCT02371668Phase 2Results posted
• Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and AboveCompletedNCT02369341Phase 3Results posted
• Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated InfluenzaCompletedNCT02369159Phase 3Results posted
• A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A InfectionCompletedNCT02293863Phase 2Results posted
• Inactivated Influenza Via Jet InjectionCompletedNCT02290691Phase 4Results posted
• Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With InfluenzaCompletedNCT02287467Phase 3Results posted
• Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of AgeCompletedNCT02285998Phase 3Results posted
• System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician AlertsCompletedNCT02266277Not applicableResults posted
• Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea ChildrenCompletedNCT02263131Phase 3Results posted
• A Pilot Study to Assess the Immunogenicity and Reactogenicity of High Versus Standard Dose TIVCompletedNCT02263040Phase 1/2Results posted
• Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in AdultsCompletedNCT02258334Phase 4Results posted
• Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult SubjectsCompletedNCT02256488Phase 3Results posted
• Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05CompletedNCT02255409Phase 3Results posted
• Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.CompletedNCT02255279Phase 3Results posted
• Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and AdolescentsCompletedNCT02250274Phase 4Results posted
• Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of AgeCompletedNCT02242643Phase 3Results posted
• Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, ChinaCompletedNCT02228980Phase 4Results posted
• Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza VaccineCompletedNCT02222870Phase 4Results posted
• Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and OlderCompletedNCT02218697Phase 3Results posted
• A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.CompletedNCT02214225Phase 3Results posted
• A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 YearsCompletedNCT02212106Phase 4Results posted
• A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and ChildrenCompletedNCT02207413Phase 3Results posted
• Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1CompletedNCT02171819Phase 1Results posted
• 4 Pillars Toolkit for Adolescent VaccinationCompletedNCT02165722Not applicableResults posted
• Systems Biology of Flu Vaccine in Healthy Adults With and Without the Use of AntibioticsCompletedNCT02154061Not applicableResults posted
• Immunogenicity of H5N1 Vaccine Following H5N2CompletedNCT02153671Phase 2Results posted
• Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)CompletedNCT02141581Phase 4Results posted
• The Influence of Chronic CMV Infection on Influenza Vaccine ResponsesCompletedNCT02134184Phase 4Results posted
• B-cell Immunity to Influenza (SLVP017)- Year 1, 2009CompletedNCT02133781Phase 4Results posted
• Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in ChildrenCompletedNCT02072174Phase 4Results posted
• A Study to Evaluate the Efficacy and Safety of CT-P27 in an Influenza Challenge ModelCompletedNCT02071914Phase 2Results posted
• Statin Therapy in Acute InfluenzaCompletedNCT02056340Phase 2Results posted
• Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months OldCompletedNCT02035696Phase 1/2Results posted
• Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With InfluenzaTerminatedNCT02014649Phase 1/2Results posted
• A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related ComplicationsCompletedNCT01998477Phase 3Results posted
• Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years OldCompletedNCT01992107Phase 3Results posted
• Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and OlderCompletedNCT01992094Phase 3Results posted
• T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009CompletedNCT01987349Phase 4Results posted
• Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/CALIFORNIA/66/395 (H2N2) Influenza VaccineCompletedNCT01982331Phase 1Results posted
• Immune and Hormone Response to Influenza VaccineCompletedNCT01978262Phase 4Results posted
• Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of AgeCompletedNCT01974895Phase 2Results posted
• PregText: Feasibility of Monitoring Influenza Vaccine Safety in Pregnant Women Using Text MessagingCompletedNCT01974050Not applicableResults posted
• Evaluation of Anti-Hemagglutinin (Anti-HA) Antibodies as Protection From the Flu in Healthy PeopleCompletedNCT01971255Phase 1/2Results posted
• Study of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in TaiwanCompletedNCT01967784Phase 3Results posted
• Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.CompletedNCT01964989Phase 3Results posted
• Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)CompletedNCT01959945Phase 3Results posted
• Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and OlderCompletedNCT01949090Phase 2Results posted
• Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in AdultsCompletedNCT01946438Phase 4Results posted

← Influenza, Human overview